Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 27;7(1):78.
doi: 10.1186/1752-153X-7-78.

Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents

Affiliations

Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents

Jiangke Qin et al. Chem Cent J. .

Abstract

Background: Alzheimer's disease (AD), a progressive and degenerative disorder, has become one of the severe problems among the aged population all over the world. To use cholinesterase inhibitor drugs has become the most predominant treatment strategy for AD.

Results: A series of novel 1, 3-dihydroxyxanthone Mannich bases derivatives (1a ~ 4e) were synthesized, structure elucidated and evaluated for anti-cholinesterase activity. The result showed that most of the target compounds exhibited moderate to good inhibitory activities with the IC50 values at micromole level concentration against both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The preliminary structure-activity indicated that: (i) The alkoxy or alkenoxy substituents in the position 3 of xanthone have a positive influence on the inhibition potency; (ii) types of dialkylamine methyl in position 2 of xanthone affected cholinesterase activities and AChE/BuChE selectivity. Among them, 2-((diethylamino)methyl)-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one showed potent inhibitory activity against AChE with the IC50 value of 2.61 ± 0.13 μM and the best inhibitory activity against BuChE with the IC50 value of 0.51 ± 0.01 μM. The results of a mixed-type manner in enzyme kinetic experiment and molecular docking study for 2-((diethylamino)methyl)-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one demonstrated that the Mannich base derivatives were likely to bind to the active site (AS) and the peripheral anionic site (PAS) of cholinesterases.

Conclusions: This study suggested that 1, 3-dihydroxyxanthone Mannich base derivatives were potential dual inhibitors of both AChE and BuChE, which may be considered as a kind of novel drug candidates for treatment of AD.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
Synthetic route of 1, 3-dihydroxyxanthone mannich base derivatives.
Figure 1
Figure 1
Main connectivities found in the HMBC of Compound 2c.
Figure 2
Figure 2
Effects of substitution in position 2 of xanthone against AChE and BuChE, respectively. 1, 2, 3, 4 represent hydroxyl, methoxyl, allyloxy, prenylated oxyl substituted in the position 3 of xanthone, respectively. a, b, c, d, e represent diethylamine methyl, dimethylamine methyl, pyrrolidinyl methyl, piperidinyl methyl, morpholino methyl substituted in the position 2 of xanthone, respectively.
Figure 3
Figure 3
Effects of substitution in position 3 of xanthone against AChE and BuChE, respectively. 1, 2, 3, 4 represent hydroxyl, methoxyl, allyloxy, prenylated oxyl substituted in the position 3 of xanthone, respectively. a, b, c, d, e represent diethylamine methyl, dimethylamine methyl, pyrrolidinyl methyl, piperidinyl methyl, morpholino methyl substituted in the position 2 of xanthone, respectively.
Figure 4
Figure 4
Lineweaver-Burk plots of AChE and BuChE inhibitory activity in the presence of compound 4b.
Figure 5
Figure 5
The binding mode research of compound 4b on AChE by docking simulations. (A) Binding interactions with selected residues of the active site for compound 4b. (B) The MOLCAD surfaces displayed with cavity depth potential of the binding pocket. (C) The MOLCAD surfaces of the binding pocket displayed with lipophilic potential.
Figure 6
Figure 6
The binding mode research of compound 4b on BuChE by docking simulations. (A) The binding interactions with selected residues of the active site for compound 4b. (B) The MOLCAD surfaces displayed with cavity depth potential of the binding pocket. (C) The MOLCAD hydrogen bonding surfaces of the binding pocket.

Similar articles

Cited by

References

    1. Wright CI, Geula C, Mesulam MM. Neuroglial cholinesterases in the normal brain and in Alzheimer’s disease: Relationship to plaques, tangles and patterns of selective vulnerability. Ann Neurol. 1993;34:373–384. doi: 10.1002/ana.410340312. - DOI - PubMed
    1. Price DL, Sisodia SS, Borchelt DR. Alzheimer disease-when and why? Nat Genet. 1998;19:314–316. doi: 10.1038/1196. - DOI - PubMed
    1. Luo Y. Alzheimer’s disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extract. Life Sci. 2006;78:2066–2072. doi: 10.1016/j.lfs.2005.12.004. - DOI - PubMed
    1. Lau LF, Schachter JB, Seymour PA, Sanner MA. Tau protein phosphorylation as a pherapeutic parget in Alzheimer’s pisease. Curr Top Med Chem. 2002;2:395–415. doi: 10.2174/1568026024607526. - DOI - PubMed
    1. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs. 2002;16:811–824. doi: 10.2165/00023210-200216120-00003. - DOI - PubMed

LinkOut - more resources